Alaunos Therapeutics Q4 2025 Earnings Results & Report

Alaunos Therapeutics EPS Results

• Actual EPS: -$0.36
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A
• EPS Beat Rate: 5 of last 8 quarters

Alaunos Therapeutics Revenue Results

• Actual Revenue: $0.00 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Alaunos Therapeutics (NASDAQ:TCRT) is a biotechnology company focused on developing genetically engineered T-cell therapies for the treatment of cancer, particularly solid tumors. Its research centers on T-cell receptor (TCR) therapies, which are designed to equip a patient’s immune cells to recognize and attack tumor-specific targets.

The company’s development programs have included TCR-T candidates directed at cancer-associated antigens such as NY-ESO-1 and LAGE-1a. Alaunos has also worked on a TCR library approach intended to support the development of personalized therapies targeting tumor mutations. These programs have been investigated primarily through early-stage clinical and research activities.

Alaunos was formerly known as Ziopharm Oncology, adopting its current name in 2022. Its work has involved collaborations with academic and research institutions, including the National Cancer Institute, and has primarily focused on cancer immunotherapy research in the United States. The company’s publicly reported activities and development programs have evolved over time, and investors should consult its latest filings for current operational and clinical updates.